Table1.
Characteristics of 14 patients with gliomas used for gbMSC isolation in the current study
| Specimen | Age (years)a | Sex | Pathological diagnosis | Grade | Passage at experiment | CD90 expression in gbMSCs (%) |
|---|---|---|---|---|---|---|
| AC-11 | 29 | M | Astrocytoma | Ill | 3 | 20.1 |
| GBM-13 | 53 | F | GBM | IV | 2 | 21.3 |
| AC-16 | 58 | F | Astrocytoma | Ill | 2 | 19.2 |
| ODG-18 | 36 | M | Oligodendroglioma | II | 3 | 13.5 |
| GBM-21 | 35 | F | GBM | IV | 2 | 21.7 |
| GBM-23 | 59 | M | GBM | IV | 3 | 25.9 |
| AC-24 | 45 | M | Astrocytoma | Ill | 3 | 18.9 |
| GBM-31 | 58 | M | GBM | IV | 3 | 19.8 |
| GBM-32 | 56 | M | GBM | IV | 4 | 23.8 |
| AC-35 | 62 | F | Astrocytoma | II | 2 | 17.9 |
| GBM-35 | 79 | F | GBM | IV | 2 | 22.1 |
| GBM-71 | 61 | F | GBM | IV | 4 | 20.3 |
| AC-73 | 36 | F | Astrocytoma | Ill | 3 | 19.8 |
| AV-76 | 38 | M | Astrocytoma | IV | 2 | 21.5 |
aAt the time of diagnosis